|Product Overview:||Recombinant Human BMP8B (Ala264-His402) was expressed in CHO.|
|Description:||BMP-8, also known as osteogenic protein 2 (OP-2), was first isolated from a hippocampal library in a screen to identify relatives of BMP-7/OP-1. BMPs are a family of structurally and functionally related proteins and represent a subfamily of the transforming growth factor beta (TGF-beta ) superfamily. BMPs are involved in a wide range of processes including embryogenesis, tissue morphogenesis, cell differentiation and migration, and tumorigenesis. Cellular responses to BMPs are mediated by hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. BMP-8a and BMP-8b, produced from separate genes, share 98% aa sequence identity in human but only 74% in mouse within the mature regions. Human BMP-8b is synthesized as a 402 aa precursor protein that is cleaved between Arg263 and Ala264 to release the C-terminal mature protein. Mature human BMP-8b shares 91% and 71% aa sequence identity with mouse mature BMP-8a and -8b, respectively. BMP-8a is expressed during pregnancy in the deciduum and trophoblast cells, by inner root sheath cells of developing hair follicles, and by the epididymis and spermatids. In the mouse it cooperates with BMP-7 in the maintenance of spermatogenesis but is not required for the initiation of spermatogenesis. BMP-8b, in contrast, is required for both the initiation and maintenance of spermatogenesis. BMP-8a is induced during osteoblast differentiation at the onset of mineralization and during the osteogenic phase of bone repair in osteoblasts and osteocytes. BMP-8b is also highly expressed in osteosarcomas and pancreatic cancer, and it contributes to tumor progression. BMP-8b is also expressed in adipose tissue and the hypothalamus where it contributes to the regulation of energy balance and thermogenesis.|
|Predicted N Terminal:||Ala264|
|Form:||Lyophilized from a 0.2 μm filtered solution in HCl.|
|Bio-activity:||Measured by its ability to inhibit the cell growth of DU145 human prostate carcinoma cells. Miyazaki, H. et al. (2004) Oncogene 23:9326. The ED50 for this effect is 0.7-3.5 μg/mL.|
|Molecular Mass:||Predicted Molecular Mass: 16 kDa
SDS-PAGE: 17-20 kDa, reducing conditions
|Endotoxin:||<0.1 EU per 1 μg of the protein by the LAL method.|
|Purity:||>85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.|
|Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
|Reconstitution:||Reconstitute at 250 μg/mL in 4 mM HCl.|
|Gene Name:||BMP8B bone morphogenetic protein 8b [ Homo sapiens ]|
|Synonyms:||BMP8B; bone morphogenetic protein 8b; BMP8, bone morphogenetic protein 8 (osteogenic protein 2); bone morphogenetic protein 8B; OP 2; osteogenic protein 2; BMP-8; BMP-8B; bone morphogenetic protein 8 (osteogenic protein 2); dJ118J21.1 (bone morphogenetic protein 8 (osteogenic protein 2)); OP2; BMP8; MGC131757;|
Price does not include shipping and packaging costs.Request quote for final price.